PS01.05 Surgical and Clinical Outcomes With Neoadjuvant Atezolizumab in Resectable Stage IB–IIIB NSCLC: LCMC3 Trial Primary Analysis-Reference-Cited by-同舟云学术

PS01.05 Surgical and Clinical Outcomes With Neoadjuvant Atezolizumab in Resectable Stage IB–IIIB NSCLC: LCMC3 Trial Primary Analysis

Published:2021-03 Issue:3 Volume:16 Page:S59-S61
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Lee J.,Chaft J.,Nicholas A.,Patterson A.,Waqar S.,Toloza E.,Haura E.,Raz D.,Reckamp K.,Merritt R.,Owen D.,Finley D.,Mcnamee C.,Blasberg J.,Garon E.,Mitchell J.,Doebele R.,Baciewicz F.,Nagasaka M.,Pass H.,Schulze K.,Phan S.,Johnson A.,Bunn P.,Johnson B.,Kris M.,Kwiatkowski D.,Wistuba I.,Carbone D.,Rusch V.

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Review of Immunotherapy in Non-Small-Cell Lung Cancer;Current Oncology;2024-06-17

2. Clinical outcomes associated with neoadjuvant therapy for the treatment of resectable non‐small cell lung cancer in real‐world practice;The Clinical Respiratory Journal;2024-05

3. A Review of the Current Approach and Treatment Landscape for Stage III Non-Small Cell Lung Cancer;Journal of Clinical Medicine;2024-04-30

4. A review of perioperative treatment strategies with immunotherapy and tyrosine kinase inhibitors in resectable and stage IIIA-N2 non-small cell lung cancer;Frontiers in Oncology;2024-03-27

5. Pathological complete response to neoadjuvant therapy with serplulimab and chemotherapy in stage IIIB small cell lung cancer: a case report and literature review;Frontiers in Immunology;2024-01-18